Biotinidase Deficiency
Biotinidase Deficiency - Related Videos
01:25
Capital Deficiency in Liquidation: II
0 Views •
2026
A capital deficiency occurs when a partner's capital account has a debit balance during partnership liquidation. It may result from operating losses, excessive drawings, or losses from the sale of partnership assets. During liquidation, noncash assets are sold, liabilities are paid, gains or losses are allocated to the partners, and the remaining cash is distributed based on the partners' capital balances.Example: Ace Company decides to liquidate because it is nearing bankruptcy. Noncash assets...
01:30
No Capital Deficiency in Liquidation
0 Views •
2026
In accounting, liquidation without capital deficiency is a structured process that enables a partnership to dissolve equitably when partners possess sufficient capital to cover all liabilities and allocated losses. This condition ensures that no partner is required to contribute additional funds to the partnership, streamlining the dissolution procedure.The liquidation process begins with conversion of noncash assets into cash. When these assets are sold, any difference between the sale price...
01:30
Capital Deficiency in Liquidation: I
0 Views •
2026
During the liquidation of a partnership, a capital deficiency occurs when a partner’s capital account becomes negative after accounting for allocated losses and the payment of liabilities. Resolving such deficiencies is a critical step before the remaining assets can be distributed. However, complications arise when a partner is unable or unwilling to contribute additional funds to eliminate their deficiency.In cases where a partner cannot satisfy their capital deficiency, the loss must be...
04:55
A Simple Mechanical Procedure to Create Limbal Stem Cell Deficiency in Mouse
0 Views •
Cited by 11 •
2016
The following article provides an easy, reproducible technique to effectively create a sustainable mouse model of limbal stem cell deficiency (LSCD). This animal model is useful in testing and comparing the efficacy of treatments for limbal stem cell diseases.
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
0 Views •
Cited by 22 •
2010
Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.
FAQs
Biotinidase deficiency can disrupt multiple pathways because biotin must be available as a cofactor for several carboxylase enzymes. Reduced recycling limits the biotin supply supporting fatty-acid synthesis, amino-acid metabolism, and gluconeogenesis. These pathways perform different tasks, but their shared dependence on biotin links the enzyme defect to broad metabolic stress rather than to a single isolated biochemical function.
During protein breakdown, biocytin and biotinylated peptides release biotin-containing material that normally can be processed for reuse. Low biotinidase activity interferes with this recovery step, so less biotin becomes available again for carboxylase-dependent reactions. This recycling defect helps explain why ongoing supplementation is relevant: it supports biotin availability despite the underlying enzyme abnormality.
Metabolic stress from inadequate biotin recycling can affect tissues whose functions depend on the affected carboxylase reactions. The possible consequences include seizures, developmental delay, hypotonia, hearing or vision problems, and skin abnormalities. The range of findings reflects the broad biological roles of the disrupted pathways, rather than damage limited to one organ or one type of tissue.
A screening result is followed by confirmatory evaluation rather than being treated as a final diagnosis. Confirmation can include measuring biotinidase enzyme activity and performing genetic testing. Using these approaches helps establish whether the suspected recycling defect is present and provides a stronger basis for beginning appropriate management before metabolic complications become more severe.
Enzyme testing examines the functional activity of biotinidase, showing whether the recycling step is impaired. Genetic testing investigates the inherited basis of that abnormality. Together, the tests connect biochemical function with genetic information, which is useful for confirming the condition and placing the laboratory findings within an inherited metabolic framework.
Early detection allows oral biotin supplementation to begin before metabolic stress causes preventable complications. Because newborn screening can identify affected infants and follow-up testing can confirm the finding, care may start during a period when symptoms are absent or limited. Lifelong supplementation then supports biotin availability and helps reduce the risk of ongoing pathway disruption.